Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
出版年份 2022 全文链接
标题
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
作者
关键词
-
出版物
SCHIZOPHRENIA BULLETIN
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2022-01-05
DOI
10.1093/schbul/sbac001
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
- (2021) Masaomi Iyo et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
- (2020) Christoph U. Correll et al. JAMA Psychiatry
- Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
- (2020) Christoph U. Correll et al. npj Schizophrenia
- Lurasidone in the treatment of schizophrenia: Results of a double‐blind, placebo‐controlled trial in Asian patients
- (2019) Teruhiko Higuchi et al. Asia-Pacific Psychiatry
- Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats
- (2019) Gavin P. Reynolds et al. Clinical Psychopharmacology and Neuroscience
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
- (2019) Maximilian Huhn et al. LANCET
- Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
- (2019) Stephen J. Kaar et al. NEUROPHARMACOLOGY
- Effects of long-term antipsychotics treatment on body weight: A population-based cohort study
- (2019) Juan Carlos Bazo-Alvarez et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia
- (2019) Stefan Leucht et al. AMERICAN JOURNAL OF PSYCHIATRY
- Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study
- (2018) Jun Ishigooka et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- One-stage dose–response meta-analysis for aggregated data
- (2018) Alessio Crippa et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study
- (2018) Zheng Tong et al. BMC Medical Research Methodology
- How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis
- (2017) Yikang Zhu et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
- (2017) Spyridon Siafis et al. Current Neuropharmacology
- Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method
- (2017) Philipp H. Rothe et al. SCHIZOPHRENIA RESEARCH
- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
- (2016) Jeffrey A. Lieberman et al. BIOLOGICAL PSYCHIATRY
- Dose-response meta-analysis of differences in means
- (2016) Alessio Crippa et al. BMC Medical Research Methodology
- Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control
- (2016) Ronald Landbloom et al. CNS SPECTRUMS
- Cariprazine in the treatment of schizophrenia
- (2016) Suresh Durgam et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia
- (2016) Antony Loebel et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia
- (2016) Azmi F. Nasser et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study
- (2016) Toshihiko Kinoshita et al. PSYCHOPHARMACOLOGY
- Dose Equivalents for Antipsychotic Drugs: The DDD Method: Table 1.
- (2016) Stefan Leucht et al. SCHIZOPHRENIA BULLETIN
- AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study
- (2016) Robert E. Litman et al. SCHIZOPHRENIA RESEARCH
- Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies
- (2016) Christoph U. Correll et al. SCHIZOPHRENIA RESEARCH
- Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment
- (2016) Mette Ø. Nielsen et al. JAMA Psychiatry
- Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia
- (2016) Myrto T. Samara et al. JAMA Psychiatry
- Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
- (2015) Christoph U. Correll et al. AMERICAN JOURNAL OF PSYCHIATRY
- Cariprazine in Acute Exacerbation of Schizophrenia
- (2015) Suresh Durgam et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia
- (2015) Herbert Y. Meltzer et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia
- (2015) John M. Kane et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method
- (2015) Stefan Leucht et al. SCHIZOPHRENIA BULLETIN
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
- (2015) John M. Kane et al. SCHIZOPHRENIA RESEARCH
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Weight gain and antipsychotics: a drug safety review
- (2014) Richard Musil et al. Expert Opinion On Drug Safety
- Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia
- (2014) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- The Selective Neurokinin 3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia
- (2014) Robert E. Litman et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia
- (2014) Joan H.Q. Shen et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
- (2014) Maarten Bak et al. PLoS One
- Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
- (2014) S. Leucht et al. SCHIZOPHRENIA BULLETIN
- A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia
- (2014) H.Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- EFFICACY AND SAFETY OF NOVEL DOPAMINE SEROTONIN STABILIZER RP 5063 IN ACUTE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
- (2014) Marc Cantillon SCHIZOPHRENIA RESEARCH
- An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
- (2014) Suresh Durgam et al. SCHIZOPHRENIA RESEARCH
- High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms
- (2013) Donald C. Goff et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study
- (2013) Henry A. Nasrallah et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial
- (2013) Antony Loebel et al. SCHIZOPHRENIA RESEARCH
- Imputation of response rates from means and standard deviations in schizophrenia
- (2013) Myrto T. Samara et al. SCHIZOPHRENIA RESEARCH
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
- (2012) Masaaki Ogasa et al. PSYCHOPHARMACOLOGY
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
- (2011) Herbert Y. Meltzer et al. AMERICAN JOURNAL OF PSYCHIATRY
- A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of High-Dose Quetiapine in Patients With Persistent Symptoms of Schizophrenia or Schizoaffective Disorder
- (2011) William G. Honer et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized, Double-Blind, Parallel-Group, Fixed-Dose, Clinical Trial of Quetiapine at 600 Versus 1200 mg/d for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder
- (2011) Jean-Pierre Lindenmayer et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Management of antipsychotic-related weight gain
- (2010) Lawrence Maayan et al. Expert Review of Neurotherapeutics
- Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
- (2010) Srihari Gopal et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder
- (2010) Carla M. Canuso et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia
- (2010) John M. Kane et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia
- (2010) Gahan J. Pandina et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
- (2010) Henry A Nasrallah et al. NEUROPSYCHOPHARMACOLOGY
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders
- (2009) Mario Álvarez-Jiménez et al. CNS DRUGS
- Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
- (2009) Michelle Kramer et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia
- (2009) John Lauriello et al. JOURNAL OF CLINICAL PSYCHIATRY
- Lurasidone in the Treatment of Acute Schizophrenia
- (2009) Mitsutaka Nakamura et al. JOURNAL OF CLINICAL PSYCHIATRY
- Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?
- (2009) Viktoria Simon et al. JOURNAL OF CLINICAL PSYCHIATRY
- Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder
- (2009) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
- (2008) Stefan Leucht et al. AMERICAN JOURNAL OF PSYCHIATRY
- Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia
- (2008) Andrew J. Cutler et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Efficacy of Iloperidone in the Treatment of Schizophrenia
- (2008) Steven G. Potkin et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
- (2008) S Leucht et al. MOLECULAR PSYCHIATRY
- Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
- (2008) Daniel E. Casey et al. PSYCHOPHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started